NCT06635902View on ClinicalTrials.gov

Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

December 22, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

March 31, 2029

Conditions
Sickle Cell DiseaseVaso-occlusive Pain Episode
Interventions
DRUG

L-citrulline

Intravenous L-citrulline (50 mg/kg + 9mg/kg/hr.) for 16 hours

OTHER

Placebo

Isotonic normal saline

DRUG

L-citrulline

Intravenous L-citrulline (25 mg/kg + 9mg/kg/hr.) for 16 hours

Trial Locations (1)

20010

RECRUITING

Children's National Hospital, Washington D.C.

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Suvankar Majumdar

OTHER